secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001104659-26-000393
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix provides business update; PRX-115 Phase 2 IND effective, gout market focus
--------------------------------------------------------------------------------

- PRX-115 Phase 1 data show rapid, durable urate lowering lasting 12 weeks at higher doses; Phase 2 IND effective.
- Fabry drug Elfabrio launched through Chiesi; CHMP negative opinion on E4W dosing under appeal, outcome Q1 2026.
- Fabry market projected $3.4B by 2030; Elfabrio target capture 15-20% share.
- Elelyso revenue continues via Pfizer and Fiocruz partnerships.
- New renal pipeline includes PRX-119 (long-acting DNase I) and Secarna RNA collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926000393/0001104659-26-000393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926000393/plx-20260105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer